High-dose therapy and autologous stem cell transplantation (ASCT) for systemic AL amyloidosis (AL): A report on 16 cases.

被引：0
|
作者：
Moreau, P [1 ]
Facon, T [1 ]
Leblond, V [1 ]
Attal, M [1 ]
Caillot, D [1 ]
Nedellec, G [1 ]
Huynh, A [1 ]
Bataille, R [1 ]
Harousseau, JL [1 ]
机构：
[1] DEPT HEMATOL,NANTES,FRANCE
来源：
EXPERIMENTAL HEMATOLOGY | 1997年 / 25卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：205 / 205
页数：1
相关论文
共 50 条
  • [41] Effect of severe hypoalbuminemia on toxicity of high-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis
    Lee, S. Y.
    Meehan, R. S.
    Seldin, D. C.
    Sloan, J. M.
    Quillen, K.
    Shelton, A.
    Brauneis, D.
    Sanchorawala, V.
    BONE MARROW TRANSPLANTATION, 2016, 51 (10) : 1318 - 1322
  • [42] High-dose melphalan and autologous peripheral blood stem cell transplantation in patients with AL amyloidosis and cardiac defibrillators
    Phull, Pooja
    Sanchorawala, Vaishali
    Brauneis, Dina
    Sloan, J. Mark
    Siddiqi, Omar K.
    Quillen, Karen
    Sarosiek, Shayna
    BONE MARROW TRANSPLANTATION, 2019, 54 (08) : 1304 - 1309
  • [43] Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis
    V Sanchorawala
    D G Wright
    K Quillen
    K T Finn
    L M Dember
    J L Berk
    G Doros
    C Fisher
    M Skinner
    D C Seldin
    Bone Marrow Transplantation, 2007, 40 : 557 - 562
  • [44] Melphalan and high-dose dexamethasone in patients with AL (primary) amyloidosis ineligible for autologous stem cell transplantation.
    Palladini, G
    Perfetti, V
    Obici, L
    Merlini, G
    BLOOD, 2002, 100 (11) : 397A - 398A
  • [45] High Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation in AL Amyloidosis
    Sanchorawala, Vaishali
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2014, 28 (06) : 1131 - +
  • [46] High-dose melphalan-autologous hematopoietic cell transplantation in systemic AL amyloidosis following daratumumab-based frontline therapy
    Mellgard, George S.
    Bhutani, Divaya
    Mapara, Markus Y.
    Maurer, Mathew S.
    Radhakrishnan, Jai
    Lentzsch, Suzanne
    Chakraborty, Rajshekhar
    BONE MARROW TRANSPLANTATION, 2024, 59 (08) : 1181 - 1183
  • [47] Spontaneous rupture of the liver in a patient with systemic AL amyloidosis undergoing treatment with high-dose melphalan and autologous stem cell transplantation: A case report with literature review
    Tam, Martin
    Seldin, David C.
    Forbes, Benjamin M.
    Connors, Lawreen H.
    Skinner, Martha
    Oran, Betul
    Quillen, Karen
    Sanchorawala, Vaishali
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2009, 16 (02): : 103 - 107
  • [48] Toxic megacolon: a life-threatening complication of high-dose therapy and autologous stem cell transplantation among patients with AL amyloidosis
    BM Hayes-Lattin
    PT Curtin
    WH Fleming
    JF Leis
    DE Stepan
    S Schubach
    RT Maziarz
    Bone Marrow Transplantation, 2002, 30 : 279 - 285
  • [49] Recent guidelines for high-dose chemotherapy and autologous stem cell transplant for systemic AL amyloidosis: a practitioner's perspective
    Bomsztyk, Joshua
    Khwaja, Jahanzaib
    Wechalekar, Ashutosh D.
    EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (09) : 781 - 788
  • [50] High-dose melphalan followed by autologous stem cell support in primary systemic AL amyloidosis with multiple organ involvement
    Shimojima, Y
    Matsuda, M
    Ishii, W
    Koyama, J
    Yamamoto, K
    Shimodaira, S
    Sakashita, K
    Koike, K
    Ikeda, S
    INTERNAL MEDICINE, 2005, 44 (05) : 484 - 489
12345